Namenda contains Memantine as its active component. It belongs to the neurology therapeutic class and is used primarily for the treatment of moderate to severe Alzheimer’s disease. The medication is supplied as an oral pill in strengths of 5 mg and 10 mg. Namenda is a prescription-only product that is regulated by the Hong Kong Department of Health and marketed by Allergan (formerly Forest Laboratories).
Memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist. By binding to the NMDA-type glutamate receptors, it moderates excessive calcium influx that can lead to neuronal injury-a process known as excitotoxicity. This modulation helps to protect brain cells and may improve or stabilize cognitive function in people with Alzheimer’s disease. The drug’s onset of action is typically within a few weeks, with peak effects seen after several months of continuous therapy. Memantine is absorbed well after oral administration, is only minimally metabolized, and is eliminated largely unchanged by the kidneys.
Namename is approved by the Hong Kong Department of Health for the treatment of moderate to severe Alzheimer’s disease. It is indicated for patients who need additional cognitive support beyond cholinesterase inhibitors or who cannot tolerate those agents. The medication is intended for adult patients; its efficacy has been demonstrated in clinical trials that showed modest improvements in cognition, activities of daily living, and behavioral symptoms compared with placebo.
Typical patient profile: adults diagnosed with Alzheimer’s disease who have progressed to a stage where memory loss, language difficulties, and functional decline are pronounced.
Research has explored memantine for other neurodegenerative conditions, such as vascular dementia, Parkinson’s disease dementia, and frontotemporal dementia. While some small-scale studies suggest potential benefits, these uses have not received regulatory approval in Hong Kong or elsewhere.
Disclaimer: Off-label use requires medical supervision and individualized risk assessment.
Special populations: Elderly patients may be more sensitive to dizziness and should start at the lower dose. Pediatric use is not established.
These effects are usually transient and may lessen as the body adapts to the medication.
If any of these occur, seek medical attention promptly.
General advice: Inform your healthcare provider of all prescription drugs, over-the-counter medicines, supplements, and herbal products before starting Namename.
Standard dosing
Day 1-7: 5 mg orally once daily (usually in the morning).
Day 8 onward: Increase to 10 mg once daily if tolerated.
The usual maintenance dose may be up to 20 mg per day (10 mg twice daily) when higher strengths are available; this article references the 5 mg and 10 mg tablets you may receive.
Special populations
Renal impairment: Reduce the dose to 5 mg once daily for CrCl 30-60 mL/min; avoid use if CrCl < 30 mL/min.
Elderly: Begin at 5 mg and titrate slowly; monitor for dizziness or confusion.
Administration
Swallow the pill whole with a glass of water.
No need to crush or chew the tablet.
Store at room temperature, away from moisture and heat.
Missed dose
Take the missed dose as soon as you remember, unless it is near the time of the next scheduled dose.
Do not double the dose to catch up.
Overdose
Symptoms may include severe drowsiness, agitation, or seizures.
Seek emergency medical care; supportive measures and gastric lavage are recommended if presentation is early.
Discontinuation
No taper is required; the drug can be stopped abruptly, but monitor for any return of symptoms.
If any new or worsening symptoms arise, contact your healthcare provider promptly.
This article provides educational information about Namename and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, you can bring Namename when traveling, but keep the medication in its original packaging with the prescription label visible. Carry a doctor's note if you are traveling to countries that require proof of prescription for controlled medicines.
Memantine is not typically included in standard employment or sports drug-screening panels, as it is not a performance-enhancing or prohibited substance.
The 5 mg tablet is usually a small, round, white tablet; the 10 mg tablet is a slightly larger, round, white tablet. Specific imprint codes may vary by manufacturer; check the packaging for details.
Yes, tablets marketed in different regions may have distinct imprint markings or colors, reflecting local manufacturing standards. The active ingredient and dosage remain the same.
Counterfeit medications can appear in any market. Purchase Namename only from licensed pharmacies or hospitals, and verify the packaging and batch number against the regulator’s database when possible.
Pilots and professional drivers should be cautious because dizziness or visual disturbances may impair performance. Evaluate personal tolerance and follow any regulatory guidance for your occupation.
Stored properly at room temperature, the tablet retains its potency until the expiration date printed on the container, typically two to three years from the manufacturing date.
Combining memantine with a cholinesterase inhibitor (e.g., donepezil) may provide complementary benefits, targeting different pathways involved in Alzheimer’s disease. This combination should only be used under physician supervision.
The price of brand-name Namename can be higher than generic memantine due to patent protections and branding. Generic versions become available after patent expiry, often leading to reduced costs. Insurance coverage and government subsidies may also affect out-of-pocket expenses.
